Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study hopes to catch cervical cancer recurrence earlier with HPV testing

NCT ID NCT07600515

Knowledge-focused Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 100 people with advanced cervical cancer who are getting radiation and chemo. Researchers want to see if checking for HPV and other markers in the blood and cervix can better predict if the cancer will come back. The goal is to find recurrences earlier and reduce the need for expensive scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients referred to ICESP

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HPV-associated squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma * Treatment-naïve * FIGO 2018 stage IB3 to IVA * Candidates for curative-intent pelvic radiotherapy with concurrent chemoradiation Exclusion Criteria: * Tumors with rare histology, such as small cell tumors, sarcomas, and lymphomas * FIGO 2018 stages IA, IB1, IB2, and IVB * Planned initial treatment is surgical or palliative * Uncertain primary tumor site (cervix vs. endometrium) * Pregnant or in the postpartum period * Immunosuppression (e.g., HIV infection with active disease, autoimmune diseases, transplant recipients)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced cervical cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced cervical cancer Prognostic biomarker

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.